Armata Pharmaceuticals, Inc. (TG1N.F)
Frankfurt · EUR · Healthcare · Biotechnology
€3.12 (+1.96%) as of
Key statistics
- Market cap
- 116.01M
- Forward P/E
- -3.39
- EPS (TTM)
- -4.5900
- Dividend yield
- 0.00%
- 52-week range
- 2.4600 – 12.7000
- Beta
- 1.41
- Revenue (TTM)
- 5.54M
- Profit margin
- 0.00%
- Volume
- 500.00
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Los Angeles, CA, United States
- Employees
- 61
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.